Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 9/20 | 0.53 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.31 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23454230 | 1.00 | CYP1A2 (0.53) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL23454378 | 1.00 | CYP1A2 (0.53) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL23454295 | 0.90 | CYP1A2 (0.55) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL23454358 | 0.90 | CYP1A2 (0.55) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL23454296 | 0.90 | CYP1A2 (0.55) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL23454252 | 0.88 | CYP1A2 (0.57) | CYP1A2SCN5ASCN1ASCN2A | |
| SCHEMBL23454375 | 0.86 | CYP1A2 (0.53) | CYP1A2SCN5A | |
| SCHEMBL23454278 | 0.86 | CYP1A2 (0.53) | CYP1A2SCN5A | |
| SCHEMBL23454280 | 0.86 | CYP1A2 (0.53) | CYP1A2SCN5A | |
| SCHEMBL24155933 | 0.82 | CYP1A2 (0.76) | CYP1A2SCN5ASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250145629-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2025-05-08 | — | — | US | disclosed |
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2024-11-19 | — | — | US | disclosed |
| US-20240043433-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2024-02-08 | — | — | US | disclosed |
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | PRAXIS PRECISION MEDICINES, INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20210171530-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-10 | — | — | US | disclosed |
| US-20210171530-A1 | ION CHANNEL MODULATORS | PRAXIS PRECISION MEDICINES, INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145939-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | SCN1A, SCN2A, SCN5A | CYP1A2 1553/4885SCN5A 3/4885SCN1A 1/4885 |
| US-20250145629-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885SCN1A 1/4885 |
| US-20240043433-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885SCN1A 1/4885 |
| US-11767325-B2 | Substituted [1,2,4]triazolo[4,3-a]pyrazines as ion channel modulators | SCN1A, SCN2A, SCN5A | CYP1A2 1403/4885SCN5A 3/4885SCN1A 1/4885 |
| US-20210171530-A1 | ION CHANNEL MODULATORS | SCN1A, SCN3A, SCN2A | CYP1A2 2873/4885SCN5A 5/4885SCN1A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.